Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04887766
Other study ID # GS-300-001
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date July 1, 2022
Est. completion date December 31, 2023

Study information

Verified date January 2022
Source Gelesis, Inc.
Contact Valerie Colletta
Phone 1-857-201-5330
Email vcolletta@gelesis.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To determine the efficacy of GS300 when administered for 24 weeks in patients with Nonalcoholic Fatty Liver Disease (NAFLD).


Description:

This is a multicenter, randomized, placebo-controlled, double-blinded, parallel-group study. Patients will be randomized 1:1 to receive either GS300 or placebo. The study includes an up to 6 weeks screening period, a 24-week treatment period, and a 1-week follow-up period. Approximately 250 patients (125 patients per arm) will be enrolled (at least 40% from each gender and at least 40% from US and 40% from Europe).


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 250
Est. completion date December 31, 2023
Est. primary completion date December 31, 2023
Accepts healthy volunteers No
Gender All
Age group 22 Years to 65 Years
Eligibility Inclusion Criteria: 1. Age = 22 years and = 65 years 2. Body Mass Index (BMI) = 27 and = 40 kilogram (kg)/meter2 (m2) 3. Negative for Hepatitis B, C and Human Immunodeficiency Virus (HIV) within 6 months of screening [HbsAg negative and Hepatitis C Virus (HCV) RNA negative; subjects treated and cured of HCV must have completed treatment and tested negative for HCV at least 2 years prior to study enrollment] 4. Fibroscan CAP score > 300 decibels (dB)/m 5. Stable body weight defined as less than 5% change in body weight in the 3 months prior to screening (per patient report) 6. Approximately 250 patients (approximately 125 patients per treatment arm) 1. Prediabetes i) Untreated prediabetic patients with FPG = 100 mg/ dL (= 5.6 mmol/L) and < 126 mg/dL (< 7.0 mmol/L) at both Screening Visits with HbA1c = 6.4% (= 46 mmol/mol) - if only one value is within this range, the other value should not be = 126 mg/dL (= 7.0 mmol/L) and HbA1c should be = 5.7% (= 39 mmol/mol) and = 6.4% (= 46 mmol/mol) ii) Drug-treated (metformin) prediabetic patients with FPG = 70 mg/dL (= 3.9 mmol/L) and < 126 mg/dL (< 7.0 mmol/L) at both Screening Visits 2. Type 2 Diabetes i) Untreated type 2 diabetic patients with FPG = 200 mg/dL (= 11.2 mmol/L) at both Screening Visits and either FPG = 126 mg/dL (= 7.0 mmol/L) at both Screening Visits or FPG < 126 mg/dL (< 7.0 mmol/L) at one or both Screening Visits with HbA1c = 6.5% (= 48 mmol/mol) ii) Drug-treated [metformin and/or dipeptidyl peptidase-4 (DPP-4) inhibitors, and/or insulin] type 2 diabetic patients with FPG = 70 mg/dL (= 3.9 mmol/L) and = 270 mg/dL (= 15.1 mmol/L) at both Screening Visits Note, approximately 10% to 20% of enrolled Type 2 diabetic patients will be on insulin therapy 3. Normoglycemia (up to approximately 10% of patients) Normoglycemic patients with FPG = 70 mg/dL (= 3.9 mmol/L) and < 100 mg/ dL (< 5.6 mmol/L) at both Screening Visits with HbA1c < 5.7% (< 39 mmol/mol) and HOMA-IR = 3.0 7. MRI PDFF = 10% 8. Willing to sign the ICF prior to any study related procedures Exclusion Criteria: 1. Self-reported alcohol intake > 20 gram (g)/day for women and > 30 g/day for men (on average per day) as per medical history 2. Alcohol Use Disorders Identification Test (AUDIT) questionnaire: AUDIT-C score of = 4 in men and = 3 in women will be followed by a full AUDIT questionnaire by interview with patients excluded for score = 8 3. Prior liver transplant 4. Liver cirrhosis as evidenced by any of the following: - Serum albumin < 3.5 g/dL (0.53 mmol/L) - INR > 1.3 (unless due to anticoagulant therapy) - AST/ALT ratio = 2 - Direct bilirubin > 0.3 mg/dL (5.13 micromol (micromol)/L) - Platelet count < 150,000/microL 5. History or evidence of other chronic liver diseases, including, but not limited to the following: - Current active autoimmune hepatitis - Primary biliary cholangitis (PBC) - Primary sclerosing cholangitis - Wilson's disease - Alpha-1-antitrypsin (A1AT) deficiency - Hemochromatosis - Drug-induced liver disease, as defined on the basis of typical exposure and history - Bile duct obstruction - Suspected or proven liver cancer - History of hepatic encephalopathy - Portal hypertension (esophageal varices, ascites, splenomegaly) 6. History of gastric surgery (up to 10% patients with history of gastric bypass or sleeve gastrectomy may be enrolled if the surgery occurred more than 6 months prior to enrollment and patients had a weight change < 5% during the 3 months prior to enrollment) 7. Angina, coronary bypass, or myocardial infarction within 6 months prior to Screening Visit 8. Inflammatory bowel disease, celiac disease, or other significant gastrointestinal disease - for example, a history of bowel obstruction without surgical correction (patients with irritable bowel syndrome may be enrolled) 9. Pregnancy 10. Absence of medically approved contraceptive methods in females of childbearing potential (e.g., hysterectomy, oral contraceptives, non-oral contraceptive medications or intrauterine device combined with a barrier method, two combined barrier methods such as diaphragm and condom or spermicide, or condom and spermicide; bilateral tubal ligation and vasectomy are not acceptable methods) 11. Type 1 Diabetes 12. HbA1c > 8.5% (> 69 mmol/mol) 13. Serum LDL-C = 160 mg/dL (= 4.15 mmol/L) 14. Serum triglycerides = 350 mg/dL (= 3.96 mmol/L) 15. Use of any medications for the treatment of diabetes within 3 months prior to enrollment. Note, metformin, DPP-4 inhibitors, and insulin at a stable dose over the last 3 months are allowed. Insulin dose variance of 20% (decrease or increase) is allowed. 16. Any change in standard of care or background therapy for liver disease or other ongoing chronic conditions within 3 months prior to enrollment, including changes in the following: - Antidiabetic medications (metformin, DPP-4 inhibitors, insulin) - Thyroid hormones - Medications treating depression - Medications treating dyslipidemia - Medications treating hypertension - Vitamin E 17. Regular/daily use of any of the following within 3 months prior to enrollment or anticipated regular/daily use during the study period: - High dose nonsteroidal anti-inflammatory drugs (NSAIDS) (equivalent of > 3,200 mg/day ibuprofen) - Systemic corticosteroids, anabolic steroids - Methotrexate, amiodarone, tamoxifen, tetracyclines, estrogens at doses greater than those used for hormone replacement, valproic acid - Probiotic supplements (yogurt is allowed) - Addictive, non-prescribed medications including amphetamines, barbiturates, cocaine, opiates, methadone and phencyclidine as per medical history or regular daily use of cannabinoids 18. Use of any anti-obesity medications (including herbal preparations) within 2 months prior to enrollment or any anticipated use during the study period 19. History of allergic reaction to carboxymethylcellulose (CMC), citric acid, sodium stearyl fumarate, raw cane sugar, gelatin, or titanium dioxide 20. Currently enrolled in another investigational device or drug study, or less than 3 months since ending another investigational device or drug study(s), or receiving other investigational treatment(s) 21. Any disease or condition that, in the opinion of the investigator or Sponsor, would interfere with study participation

Study Design


Related Conditions & MeSH terms


Intervention

Device:
GS300
Gelesis300 hydrogel in gelatin capsules
Placebo
Placebo capsules

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Gelesis, Inc.

Outcome

Type Measure Description Time frame Safety issue
Other Intestinal Permeability Intestinal permeability - Urine test (sub-population of 50 patients at selected sites). 24 Weeks
Other Vitamin Levels Serum/plasma vitamin levels (sub-population at selected sites). 24 Weeks
Other Gut Peptides Glucagon-like Peptide-1 (GLP-1), Glucagon-like Peptide-2 (GLP-2), Gastric Inhibitory Polypeptide (GIP), ghrelin, somatostatin, Cholecystokinin (CCK), Peptide YY (PYY). 24 Weeks
Primary Weight loss = 5% Proportion of patients with weight loss = 5% at Week 24. 24 Weeks
Primary Placebo-adjusted percent change in weight from Baseline to Week 24 Placebo-adjusted percent change in weight from Baseline to Week 24. 24 Weeks
Primary Relative reduction in liver fat Relative reduction in liver fat from Baseline to Week 24, as measured by hepatic Magnetic Resonance Imaging Proton Density Fat Fraction (MRI PDFF). 24 Weeks
Secondary Weight loss = 7.5% To assess reduction in weight (= 7.5%) in patients with NAFLD treated with GS300 or placebo. 24 Weeks
Secondary Weight loss = 10% To assess reduction in weight (= 10%) in patients with NAFLD treated with GS300 or placebo. 24 Weeks
Secondary To evaluate the percentage of patients with = 30% relative reduction in liver fat To evaluate the percentage of patients with = 30% relative reduction in liver fat in patients treated with GS300 or placebo. 24 Weeks
Secondary To assess placebo-adjusted waist circumference reduction To assess placebo-adjusted waist circumference reduction after 24 weeks of treatment with GS300 or placebo. 24 Weeks
Secondary To assess the impact of GS300 on glycemic control in patients with NAFLD To assess the impact of GS300 on glycemic control in patients with NAFLD treated with GS300 or placebo. 24 Weeks
Secondary To assess the impact of GS300 on liver enzymes in patients with NAFLD To assess the impact of GS300 on liver enzymes in patients with NAFLD treated with GS300 or placebo. 24 Weeks
See also
  Status Clinical Trial Phase
Completed NCT04506996 - Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2 N/A
Active, not recruiting NCT04420936 - Pragmatic Research in Healthcare Settings to Improve Diabetes and Obesity Prevention and Care for Our Program N/A
Terminated NCT03316105 - Effect of T6 Dermatome Electrical Stimulation on Gastroduodenal Motility in Healthy Volunteers N/A
Completed NCT03700736 - The Healthy Moms Study: Comparison of a Post-Partum Weight Loss Intervention Delivered Via Facebook or In-Person Groups N/A
Active, not recruiting NCT04353726 - Knowledge-based Dietary Weight Management. N/A
Completed NCT02948283 - Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia Phase 1
Completed NCT03377244 - Healthy Body Healthy Souls in the Marshallese Population N/A
Completed NCT02877004 - LLLT for Reducing Waste Circumference and Weight N/A
Active, not recruiting NCT04327141 - Low Sugar Protein Pacing, Intermittent Fasting Diet in Men and Women N/A
Completed NCT03929198 - Translation of Pritikin Program to the Community N/A
Recruiting NCT05249465 - Spark: Finding the Optimal Tracking Strategy for Weight Loss in a Digital Health Intervention N/A
Recruiting NCT05942326 - Sleep Goal-focused Online Access to Lifestyle Support N/A
Completed NCT00535600 - Effects of Bariatric Surgery on Insulin
Not yet recruiting NCT03601273 - Bariatric Embolization Trial for the Obese Nonsurgical Phase 1
Active, not recruiting NCT04357119 - Common Limb Length in One-anastomosis Gastric Bypass N/A
Completed NCT03139760 - POWERSforID: A Telehealth Weight Management System for Adults With Intellectual Disability N/A
Completed NCT03210207 - Gastric Plication in Mexican Patients N/A
Completed NCT02948517 - Time Restricted Feeding for Weight Loss and Cardio-protection N/A
Completed NCT02945410 - Effect of Caloric Restriction and Protein Intake on Metabolism and Anabolic Sensitivity N/A
Recruiting NCT02559479 - A Study to Assess the Effect of a Normal vs. High Protein Diets in Carbohydrates Metabolism in Obese Subjects With Diabetes or Prediabetes N/A